Search Results 11-20 of 17480 for anti-TNF drugs

1. Crohn's Disease Clinical Trials - Mayo Clinic Research

   The purpose of this study is to determine whether adding low dose methotrexate to anti -TNF therapy is more effective than treatment with anti-TNF therapy alone ...

2. Advances in the treatment of Crohn's disease and ulcerative colitis - Mayo Clinic

   Within the United States, four anti-TNF agents are currently approved for the treatment of IBD — infliximab, adalimumab, certolizumab pegol and golimumab.

3. Medicines that treat ulcerative colitis - Mayo Clinic

   Anti-inflammatory medications · Aminosalicylates · Corticosteroids ; Biologic medicines · Anti-TNF agents: TNF blockers · Interleukin‑12 and interleukin‑23 pathway ...

4. A Study To Assess Change In Disease Activity And Adverse Events Of Oral Upadacitinib In Adult And Adolescent Participants With Moderate To Severe Hidradenitis Suppurativa Who Have Failed Anti-TNF Therapy - Mayo Clinic

   ... anti-tumor necrosis factor (TNF) therapy. Adverse events and change in disease activity will be assessed. Upadacitinib is an approved drug for ulcerative ...

5. Crohn's Disease Clinical Trials - Mayo Clinic Research

   ... medications such as the anti-Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ...

6. A Study to Evaluate both the Efficacy and Safety Profile of CP-690,550 in Patients with Moderately to Severely Active Ulcerative Colitis - Mayo Clinic

   ... anti-TNF-alpha therapy. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health ...

7. A Study Of CNTO 136 (Sirukumab), A Human Anti-IL-6 Monoclonal Antibody, Administered Subcutaneously, In Patients With Active Rheumatoid Arthritis Despite Anti-TNF-Alpha Therapy (SIRROUND-T) - Mayo Clinic

   ... treatment with anti-TNF-alpha agents. Participation eligibility. Participant eligibility includes age, gender, type and stage of disease, and previous ...

8. Treatment response and management of biologics in patients with ECD - Mayo Clinic

   These include tumor necrosis factor-alpha (TNFα) inhibitors (certolizumab, infliximab, adalimumab), anti-integrin agents (vedolizumab, natalizumab), and ...

9. Crohn's Disease Clinical Trials - Mayo Clinic Research

   ... medications such as the anti-Tumor Necrosis Factor (anti-TNF) agents infliximab, adalimumab, and certolizumab. However, many CD and UC patients still ...

10. A Study to Assess Disease Activity and Safety of Subcutaneous Lutikizumab (ABT-981) in Adult Participants With Moderate to Severe Hidradenitis Suppurativa Who Have Failed Anti-Tumor Necrosis Factor (TNF) Therapy and Who Are Naïve to Biologic Therapy - Mayo Clinic

    * Must have failed anti-TNF treatment for HS. * To be eligible for the Sub-study, participants must be naïve to biologic therapy for treatment of HS.